The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009. We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues.
The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009. We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues. Learn more about How to Read a Medical Abstract in a Research Study.
Development Time of Cancer Clinical Trials Linked to Accrual Goals.
- Abstract #CRA6509.
- ASCO 2009: Development Time of Cancer Clinical Trials Linked to Accrual Goals, by Roxanne Nelson, Medscape Conference Coverage – American Society of Clinical Oncology (ASCO) 45th Annual Meeting, MedscapeToday, June 4, 2009 (free registration required to view article).
Physicians Need to Address Prescription Costs With Patients Who Participate In Clinical Trials.
- Abstract #9503.
- ASCO 2009: Physicians Need to Address Cost of Cancer Care With Patients, by Roxanne Nelson, Medscape Conference Coverage – American Society of Clinical Oncology (ASCO) 45th Annual Meeting, MedscapeToday, May 18, 2009 (free registration required to view article).
Availability of Experimental Therapy Outside of Randomized Clinical Trials In Oncology.
- Abstract #6539.
- ASCO 2009: Should Experimental Cancer Therapies Be Available Outside Clinical Trials?, by Roxanne Nelson, Medscape Conference Coverage -American Society of Clinical Oncology (ASCO) 45th Annual Meeting, MedscapeToday, June 18, 2009 (free registration required to view article).
ASCO Fertility Preservation Guidelines For Cancer Patients Not Widely Followed By Oncologists.
- Abstract #9509, Abstract #CRA9508.
- ASCO 2009: Fertility Preservation Guidelines Not Widely Followed, by Roxanne Nelson, Medscape Conference Coverage – American Society of Clinical Oncology (ASCO) 45th Annual Meeting, Medscape Today, June 1, 2009 (free registration required to view article).
Ginger (Zindol®) Quells Cancer Patients’ Chemotherapy-Related Nausea.
- Abstract #9511.
- Libby’s H*O*P*E*™ Coverage.
- ASCO 2009: Ginger Helps Relieve Chemotherapy-Associated Nausea, by Roxanne Nelson, Medscape Conference Coverage – American Society of Clinical Oncology (ASCO) 45th Annual Meeting, Medscape Today, May 15, 2009 (free registration required to view article).
- Aphios Announces Presentation of Phase II/III Clinical Trial Data on Zindol® for Cancer Chemotherapy Induced Nausea, Press Release, Aphios Corporation, May 26, 2009.
Early Treatment of Recurrent Ovarian Cancer Based Upon Rising CA-125 Levels Does Not Increase Survival.
- Abstract #e16546.
- Libby’s H*O*P*E*™ Coverage.
- Doubts on Ovarian Cancer Relapse Test, by Andrew Pollack, Health Section, Research, The New York Times (online), May 31, 2009.
- Early treatment based on rising CA125 did not improve survival in recurrent ovarian cancer, 2009 ASCO Annual Meeting, HemOncToday, May 31, 2009.
Body Mass Index (BMI) Should Be Taken Into Account When Assessing A Cancer Patient’s Vitamin D Status.
- Abstract #6625.
- Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients, News & Information, PR Newswire, June 15, 2009.
Extreme Drug Resistance (EDR) Assay Results Do Not Independently Predict Or Alter The Outcomes of Patients With Epithelial Ovarian Cancer Who Are Treated With Optimal Cytoreductive Surgery Followed By Platinum & Taxane Combination Chemotherapy in Either a Primary or Recurrent Setting.
Systematic Review Of Past Study Results For Use of Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Preliminary Results From Phase II Study of Oxaliplatin+Docetaxel+Bevacizumab As First Line Treatment of Advanced Ovarian Cancer Show 62% Overall Response Rate & 70% One-Year Progression Free Survival.
Combined Weekly Docetaxel + Gemcitabine In Relapsed Ovarian Cancer & Peritoneal Cancer Produces 59% Overall Response Rate.
A Phase II Trial of Irinotecan & Oral Etoposide Chemotherapy in Recurrent Ovarian Cancer Patients Produces 47% Overall Response Rate & 81% Clinical Benefit Rate.
Weekly Bevacizumab & Pegylated Liposomal Doxorubicin Produce 55% Clinical Benefit Rate In Progressing/Recurrent Ovarian Cancer Patients.
Phase II Study of Belotecan (CKD-602)+ Carboplatin Demonstrates 53% Overall Response Rate in Recurrent Ovarian Cancer Patients.
Single Agent Voreloxin Produces 11% Overall Response Rate & 52% Disease Control Rate in Phase II Study Involving Women with Platinum-Resistant Ovarian Cancer.
- Abstract #5559.
- Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting, Press Release, Sunesis Pharmaceuticals, Inc., June 1, 2009.
A Phase II Study of Patupilone In Patients With Platinum Refractory/Resistant Ovarian, Primary Fallopian, or Peritoneal Cancer Produces 48% Clinical Benefit Rate.
Trabectedin (Yondelis®) + Pegylated Liposomal Doxorubicin (PLD) Produces Better Response Than PLD Alone.
M.D. Anderson Cancer Center Finds Anti-VEGF Therapy Is Highly Effective In Patients With Ovarian Granulosa Cell Tumors.
M.D. Anderson Cancer Center Finds That Increased Angiogenesis Is A Significant Predictor Of Poor Clinical Outcome In Patients With Sex-Cord Stromal Tumors; Suggests Anti-Angiogenesis Therapy is Warranted For This Subtype of Ovarian Cancer.
ZYBRESTAT™ (Combretastatin A-4 phosphate) Produces 32% Confirmed Partial Response Rate (RR) in Evaluable Patients With Platinum Resistant Ovarian Cancer (25% RR if total enrolled patients used as denominator).
- Abstract #5502.
- OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting – Final Data Presentation Shows 25% Confirmed Response Rate in Relapsed Patient Population, Press Release, OXiGENE, Inc., June 1, 2009.
ASSIST-5 Trial of TELCYTA® + Pegylated Liposomal Doxorubicin Produces 12% Response Rate (With One Complete Response) in Patients With Platinum Refractory and Resistant Ovarian Cancer.
- Abstract #5552.
- Telik Presents Results At ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory And Resistant Ovarian Cancer, News & Events, Telik, Inc., May 31, 2009.
Two Studies Provide Contradictory Data for Use of Carboplatin + Pegylated Liposomal Doxorubicin in Ovarian Cancer
- Abstract #LBA5508. Carboplatin + Pegylated Liposomal Doxorubicin As First Line Treatment of Advanced Ovarian Cancer Produce Similar Results to Carboplatin + Paclitaxel But With Greater Toxicity.
- Studies offer contradictory data for carboplatin plus liposomal doxorubicin in ovarian cancer, 2009 ASCO Annual Meeting, HemOncToday, June 18, 2009.
- Abstract #LBA5509. Carboplatin + Pegylated Liposomal Doxorubicin Better Than Carboplatin + Paclitaxel In Terms of Progression Free Survival & General Toxicity With Respect to Platinum Sensitive Ovarian Cancer Patients Enrolled In The CALYPSO Study of the Gynecologic Cancer Intergroup (GCIG).
- Schering’s Caelyx superior in ovarian cancer trial, News Article, Reuters Online, May 30, 2009.
OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase I Cancer Trial, Including 60% Response Rate (Based Upon Declining CA125) For Ovarian Cancer Patients.
- Abstract #3506.
- OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial, Press Release, OncoGenex Pharmaceuticals, Inc., May 30, 2009.
- A Phase 1 Study Evaluating a Second Generation Antisense Oligonucleotide (OGX-427) That Inhibits Heat Shock Protein 27 (Hsp27), Microsoft Powerpoint Presentations, OncoGenex Pharmaceuticals, Inc. [PDF Adobe Reader Doc.]
Maintenance BIBF 1120 Could Delay Disease Progression in Recurrent Ovarian Cancer.
- Abstract #5501.
- Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009, Press Release, Boehringer Ingelheim GmbH, May 15, 2009.
Oral PARP Inhibitor Olaparib (AZD2281) Effective Against BRCA-Deficient Advanced Ovarian Cancer.
Carfilzomib (PX-171-007) Produces Stable Disease For 4+ Months In One Ovarian Cancer Patient Who Failed Under Four Previous Treatment Lines – Phase II Solid Tumor Trial.
- Abstract #3515.
- Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting, News & Information, PR Newswire, May 30, 2009.
__________________________________________
About The American Society of Clinical Oncology
The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. To view 2009 ASCO Annual Meeting presentation abstracts, click here. To view 2009 ASCO Annual Meeting presentation abstracts regarding ovarian cancer, click here. To view ASCO ovarian cancer information, click here.
About Cancer.Net
Cancer.Net, formerly People Living With Cancer (PLWC), brings the expertise and resources of the American Society of Clinical Oncology (ASCO), the voice of the world’s cancer physicians, to people living with cancer and those who care for and care about them. ASCO is composed of more than 27,000 oncologists globally who are the leaders in advancing cancer care. All the information and content on Cancer.Net was developed and approved by the cancer doctors who are members of ASCO, making Cancer.Net the most up-to-date and trusted resource for cancer information on the Internet. Cancer.Net is made possible by The ASCO Cancer Foundation, which provides support for cutting-edge cancer research, professional education, and patient information.
Cancer.Net provides timely, oncologist-approved information to help patients and families make informed health-care decisions. All content is subject to a formal peer-review process by the Cancer.Net Editorial Board, composed of more than 150 medical, surgical, radiation, and pediatric oncologists, oncology nurses, social workers, and patient advocates. In addition, ASCO editorial staff reviews the content for easy readability. Cancer.Net content is reviewed on an annual basis or as needed.
To view Cancer.Net ovarian cancer information, click here.
Learn more about How to Read a Medical Abstract in a Research Study, Cancer.Net.
Libby's H*O*P*E* 